Rare Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.95 M
as on 23-10-2024
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.89 M
as on 23-10-2024
- Satisfied Charges ₹ 11.45 M
as on 23-10-2024
- Revenue 1694.87%
(FY 2023)
- Profit -60.09%
(FY 2023)
- Ebitda 8.02%
(FY 2023)
- Net Worth -141.60%
(FY 2023)
- Total Assets -22.00%
(FY 2023)
About Rare Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹6.89 M. The company has closed loans amounting to ₹1.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Pawar, Pramila Pawar, and Chandrasen Shinde serve as directors at the Company.
- CIN/LLPIN
U99999MH1989PTC054794
- Company No.
054794
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Rare Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Pawar  | Director | 21-Oct-2019 | Current |
| Pramila Pawar | Director | 21-Oct-2019 | Current |
| Chandrasen Shinde | Director | 22-May-2023 | Current |
Financial Performance and Corporate Structure Insights of Rare Pharma.
Rare Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1694.87% increase. The company also saw a substantial fall in profitability, with a 60.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 141.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rare Pharma?
In 2023, Rare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Samuh-Laxmi Chemicals (Bombay) Private Limited
Active 33 years 7 monthsRajendra Pawar and Pramila Pawar are mutual person
Badlapur Common Effluent Treatment Plant Association
Active 26 years 11 monthsRajendra Pawar and Chandrasen Shinde are mutual person
_PRIVATE_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 08 Dec 2022 | ₹6.89 M | Open |
Janakalyan Sahakari Bank Limited Creation Date: 13 Oct 2007 | ₹0.20 M | Satisfied |
Janakalyan Sahakari Bank Limited Creation Date: 13 Oct 2007 | ₹2.70 M | Satisfied |
How Many Employees Work at Rare Pharma?
Unlock and access historical data on people associated with Rare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
